{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:37:52Z","timestamp":1789699072863,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010731","name":"Faculty of Medicine, Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.oret.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T04:08:46Z","timestamp":1616818126000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy"],"prefix":"10.1016","volume":"6","author":[{"given":"Voraporn","family":"Chaikitmongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phit","family":"Upaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-722X","authenticated-orcid":false,"given":"Direk","family":"Patikulsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pichai","family":"Jirarattanasopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-0270","authenticated-orcid":false,"given":"Janejit","family":"Choovuthayakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-8694","authenticated-orcid":false,"given":"Nawat","family":"Watanachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paradee","family":"Kunavisarut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansing","family":"Ratanasukon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-1941","authenticated-orcid":false,"given":"Patama","family":"Bhurayanontachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-3817","authenticated-orcid":false,"given":"Thammasin","family":"Ingviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","article-title":"Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy","volume":"137","author":"Chaikitmongkol","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaophthalmol.2019.0449","article-title":"Appearance of polypoidal lesions in patients with polypoidal choroidal vasculopathy using swept-source optical coherence tomographic angiography","volume":"137","author":"Bo","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib3","first-page":"588","article-title":"Macular disease and subretinal neovascularization","volume":"80","author":"Yannuzzi","year":"1980","journal-title":"N\u00a0Y State J Med"},{"key":"10.1016\/j.oret.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"Koh","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST Study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib6","first-page":"417","article-title":"Criteria for diagnosis of polypoidal choroidal basculopathy","volume":"109","year":"2005","journal-title":"Nippon Ganka Zasshi"},{"key":"10.1016\/j.oret.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/IAE.0b013e318276e096","article-title":"Adjusted retreatment of polypoidal choroidal vasculopathy after combination therapy: results at 3 years","volume":"33","author":"Jeon","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10384-010-0886-x","article-title":"Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy","volume":"55","author":"Akaza","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/IAE.0b013e3181d37486","article-title":"Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up","volume":"30","author":"Leal","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2013.11.015","article-title":"Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib11","first-page":"379","article-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy","volume":"72","author":"Morizane-Hosokawa","year":"2018","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.oret.2021.03.012_bib12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the planet study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235213","article-title":"Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy","volume":"15","author":"Ito","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.oret.2021.03.012_bib16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/eye.2014.222","article-title":"Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome","volume":"28","author":"Ho","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.oret.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/IAE.0000000000000767","article-title":"One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"36","author":"Hara","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bjophthalmol-2014-305275","article-title":"Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy","volume":"99","author":"Hosokawa","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-014-2707-2","article-title":"Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy","volume":"253","author":"Ijiri","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/IAE.0000000000000229","article-title":"Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy","volume":"34","author":"Inoue","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/IAE.0000000000000933","article-title":"Aflibercept for polypoidal choroidal vasculopathy: as needed versus fixed interval dosing","volume":"36","author":"Inoue","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00417-016-3489-5","article-title":"Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT Study","volume":"255","author":"Lee","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ajo.2015.01.018","article-title":"One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome","volume":"159","author":"Oishi","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000477448","article-title":"One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in japanese patients: the APOLLO Study","volume":"238","author":"Oshima","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2021.03.012_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000488808","article-title":"Aflibercept treatment in polypoidal choroidal vasculopathy: results of a prospective study in a Caucasian population","volume":"240","author":"Wolff","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2021.03.012_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 2-year results of the PLANET Study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib27","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","article-title":"One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"122","author":"Yamamoto","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.012_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pdpdt.2019.06.004","article-title":"Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy","volume":"27","author":"Hsia","year":"2019","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.oret.2021.03.012_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2011.07.001","article-title":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab","volume":"153","author":"Tomita","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.012_bib30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0000000000002384","article-title":"Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy","volume":"40","author":"Cho","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.012_bib31","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/bjophthalmol-2014-306432","article-title":"Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study","volume":"99","author":"Koizumi","year":"2015","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:29:53Z","timestamp":1762853393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653021001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2468653021001019"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2021.03.012","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}